Literature DB >> 14968164

Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons.

V V Grigorev1, O A Dranyi, S O Bachurin.   

Abstract

Dimebon in low concentrations potentiated activity of AMPA-receptors in rat cerebellar Purkinje neurons, while memantine produced only an insignificant potentiation in a small group of these cells. In cortical neurons of rat brain memantine efficiently blocked NMDA-induced currents in dimebon-insensitive neurons. By contrast, its effect was far weaker in neurons, where the blocking action of dimebon on NMDA-receptors was most pronounced. It was hypothesized that the differences in the effects of memantine and dimebon are determined by their interaction with different sites of NMDA-receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14968164     DOI: 10.1023/b:bebm.0000017097.75818.14

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  37 in total

Review 1.  Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.

Authors:  Magali Dumont; Michael T Lin; M Flint Beal
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

3.  The rise and fall of Dimebon.

Authors:  Ilya Bezprozvanny
Journal:  Drug News Perspect       Date:  2010-10

Review 4.  Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease.

Authors:  Ilya Bezprozvanny; Mark P Mattson
Journal:  Trends Neurosci       Date:  2008-07-31       Impact factor: 13.837

Review 5.  Polycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs?

Authors:  Cornelis J Van der Schyf; Werner J Geldenhuys
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

6.  The age-related gliosis and accompanying deficit in spatial learning are unaffected by dimebon.

Authors:  Thelma R Cowley; Rodrigo Esteban González-Reyes; Jill C Richardson; David Virley; Neil Upton; Marina A Lynch
Journal:  Neurochem Res       Date:  2012-09-26       Impact factor: 3.996

Review 7.  An update on treatment and prevention strategies for Alzheimer's disease.

Authors:  Judith Neugroschl; Mary Sano
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

Review 8.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

Review 9.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

10.  Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast.

Authors:  Prashant R Bharadwaj; Giuseppe Verdile; Renae K Barr; Veer Gupta; John W Steele; M Lenard Lachenmayer; Zhenyu Yue; Michelle E Ehrlich; Gregory Petsko; Shulin Ju; Dagmar Ringe; Sonia E Sankovich; Joanne M Caine; Ian G Macreadie; Sam Gandy; Ralph N Martins
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.